Thromboprophylaxis with apixaban and the risk of pulmonary embolism in patients undergoing knee replacement surgery.

ABSTRACT: BACKGROUND:Apixaban, a novel oral anticoagulant, is also used for deep vein thrombosis (DVT) prophylaxis. In this study, we sought to critically evaluate the differences in the rates of symptomatic DVT and bleeding, and analyze the rates of pulmonary embolism (PE) in subgroups of patients from ADVANCE I and II trials given their similar indication and design. METHODS:Studies were identified through electronic literature searches of MEDLINE, clinicaltrial.gov, SCOPUS, and EMBASE up to January 2014. Phase III RCTs involving use of apixaban and enoxaparin for thromboprophylaxis in patients undergoing total knee or hip replacement were included. Study-specific odds ratios were calculated and between-study heterogeneity was assessed using the I (2) statistics. RESULTS:In three studies involving

SUBMITTER: Aryal MR 

PROVIDER: S-EPMC4558285 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature